This protocol targets patients who are serious about performance and willing to commit to a structured program
Therapeutic Research Protocol Dose: 300 600 mcg (1 2 capsules) Duration: 6 10 weeks Frequency: Once daily, preferably before physical-activity windows Cycle Interval: 3 4 weeks off before repeating Goal / Description: Used in research targeting endurance, fat oxidation, and ERR pathway activation
Q3: What are the available Ozempic strengths in the UK
The approval is supported by data from the Phase I/II TRIDENT-1 trial, where treatment with Augtyro resulted in a 58% confirmed objective response rate (cORR) in TKI-nave patients, of which 15% were complete responses
(PubMed) Morris AA, Kozich V, Santra S, et al
PLoS ONE 6 , e25612 (2011)